CoChat

Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer

Open access
Wolpin, Brian M., Ng, Kimmie, Bao, Ying, Kraft, Peter, Stampfer, Meir J., Michaud, Dominique S., Ma, Jing, Buring, Julie E., Sesso, Howard D., Lee, I-Min, Rifai, Nader, Cochrane, Barbara B., Wactawski-Wende, Jean, Chlebowski, Rowan T., Willett, Walter C., Manson, JoAnn E., Giovannucci, Edward L., Fuchs, Charles S. · 2012 · Cancer Epidemiology, Biomarkers & Prevention
Cited by 104

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background: Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting. Methods: To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case–control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls was 14.1 years in Health Professionals Follow-Up Study (HPFS), 18.3 years in Nurses' Health Study (NHS), 25.3 years in Physicians' Health Study (PHS), 12.2 years in Women's Health Initiative-Observational Study (WHI), and 14.4 years in Women's Health Study (WHS). Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH)D. Results: Mean plasma 25(OH)D was lower in cases versus controls (61.3 vs. 64.5 nmol/L, P = 0.005). In logistic regression models, plasma 25(OH)D was inversely associated with odds of pancreatic cancer. Participants in quintiles two through five had multivariable-adjusted ORs (95% confidence intervals) of 0.79 (0.56–1.10), 0.75 (0.53–1.06), 0.68 (0.48–0.97), and 0.67 (0.46–0.97; Ptrend = 0.03), respectively, compared with the bottom quintile. Compared with those with insufficient levels [25[OH]D, <50 nmol/L], ORs were 0.75 (0.58–0.98) for subjects with relative insufficiency [25[OH]D, 50 to <75 nmol/L] and 0.71 (0.52–0.97) for those with sufficient levels [25[OH]D, ≥75 nmol/L]. No increased risk was noted in subjects with 25(OH)D ≥100 nmol/L, as suggested in a prior study. In subgroup analyses, ORs for the top versus bottom quartile of 25(OH)D were 0.72 (0.48–1.08) for women, 0.73 (0.40–1.31) for men, and 0.73 (0.51–1.03) for Whites. Conclusions: Among participants in five large prospective cohorts, higher plasma levels of 25(OH)D were associated with a lower risk for pancreatic cancer. Impact: Low circulating 25(OH)D may predispose individuals to the development of pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 21(1); 82–91. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-11-0836

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 104

Metadata

Authors
Wolpin, B. M., Ng, K., Bao, Y., Kraft, P., Stampfer, M. J., Michaud, D. S., Ma, J., Buring, J. E., Sesso, H. D., Lee, I.-M., Rifai, N., Cochrane, B. B., Wactawski-Wende, J., Chlebowski, R. T., Willett, W. C., Manson, J. E., Giovannucci, E. L., & Fuchs, C. S.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2012-01-01
Volume
21
Issue
1
Pages
82-91
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2097327188
Cited by
104
References
12
FWCI
10.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1055-9965.epi-11-0836
The paper
Wolpin, B. M., Ng, K., Bao, Y., Kraft, P., Stampfer, M. J., Michaud, D. S., Ma, J., Buring, J. E., Sesso, H. D., Lee, I.-M., Rifai, N., Cochrane, B. B., Wactawski-Wende, J., Chlebowski, R. T., Willett, W. C., Manson, J. E., Giovannucci, E. L., & Fuchs, C. S. (2012). Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-11-0836

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.